对比增强CT图像上脾肝衰减比值诊断血液系统恶性肿瘤弥漫性脾受累
研究纳入70例血液系统恶性肿瘤患者及连续对照,评估门静脉期CT脾肝衰减比值能否识别淋巴瘤弥漫性脾浸润。弥漫性脾浸润者治疗前脾衰减93.48 HU,低于对照112.39 HU及治疗后113.39 HU(均p<.01);脾肝衰减比值治疗前低于对照(p<.01),治疗后显著升高(p<.001),且与FDG摄取下降呈负相关(n=10,含2例脾体积正常者)。作者建议在脾体积测量之外加用脾肝衰减比值。
要点
- 门静脉期CT脾肝衰减比值可辅助识别淋巴瘤弥漫性脾浸润,尤其脾体积正常者。
- 弥漫性脾浸润治疗前脾衰减93.48 HU,低于对照112.39 HU(p<.01)。
- 脾肝衰减比值与FDG摄取变化呈负相关(n=10),脾体积正常者亦可准确。
核心结论
- 作者建议在脾体积测量之外加用脾肝衰减比值检测淋巴瘤弥漫性脾浸润,该比值变化与FDG摄取变化呈负相关,在脾体积正常的弥漫性受累脾中亦准确。
研究设计与样本
- 研究纳入2010年12月至2018年3月间接受对比增强CT的70例恶性血液病患者,并评估连续对照者;参考标准为化疗后脾体积正常化或FDG摄取正常化。
关键影像表现/征象
- 弥漫性脾浸润者治疗前脾衰减93.48 HU,低于对照112.39 HU(p<.01)及治疗成功后113.39 HU(p<.01);脾体积治疗成功后由586.14.87 cm3降至284.90 cm3(p<.001)。
诊断标准与关键数值
- 脾肝衰减比值在治疗前显著低于对照(p<.01),治疗后显著升高(p<.001),并与FDG摄取下降呈负相关(n=10),包括2/10例脾体积正常者。
临床应用与阅片要点
- 作者建议在脾体积测量之外加用脾肝衰减比值,以检测淋巴瘤患者的弥漫性脾浸润。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: We aimed to test the hypothesis that the spleen-to-liver-attenuation ratio on portal-venous enhancement phase CT images can identify diffuse splenic infiltration in subjects with lymphoma.
METHODS: A database search yielded 70 subjects with malignant haematological diseases who underwent contrast-enhanced CT (CECT) between December 2010 and March 2018. Additionally, consecutive control subjects were evaluated. We compared the splenic volume, splenic attenuation, spleen-to-liver, spleen-to-aorta and spleen-to-musculature ratios on portal-venous phase CECT images, pre- to post-treatment and between the different lymphoma entities. The standard of reference for splenic involvement was normalisation of the spleen volume following chemotherapy or normalisation of FDG-uptake.
RESULTS: In subjects with diffuse splenic involvement, the spleen attenuation was significantly lower before treatment (93.48 HU) compared to controls (112.39 HU; p < .01) and after successful treatment (113.39 HU; p < .01). The spleen-to-liver attenuation ratio significantly increased after treatment (p < .001) and proved significantly lower at baseline when compared to control subjects (p < .01). The spleen volume significantly decreased after successful treatment (from 586.14.87 cm3 to 284.90 cm3; p < .001). Spleen-to-liver ratio significantly increased in lymphoma patients after therapy, inversely correlating with the decline in FDG-uptake (n=10) even in patients with normal-sized spleens (2/10), staying unchanged at follow-up. The outcome variables were not significantly different between the lymphoma subtypes.
CONCLUSIONS: We suggest the additional use of spleen-to-liver attenuation ratio to splenic volume alone for detection of diffuse splenic infiltration in subjects with lymphoma. The course of spleen-to-liver attenuation ratio inversely correlated with that of FDG-uptake in a subgroup of patients working accurately in normal-sized diffusely involved spleens.
KEY POINTS: • Involvement of the spleen is frequent in haematological malignancies and is important for staging and appropriate treatment. • Diffuse splenic infiltration often results in only homogeneous splenomegaly without a focal lesion, but even no or only minimal increase in splenic volume is possible. In these cases diagnosis of spleen involvement is a challenge for the radiologist. • Our data support the use of the spleen-to-liver attenuation ratio in addition to size measurements for the detection of diffuse splenic infiltration in subjects with lymphoma.
引用
- Reinert CP, Hinterleitner C, Fritz J, et al. Diagnosis of diffuse spleen involvement in haematological malignancies using a spleen-to-liver attenuation ratio on contrast-enhanced CT images. Eur Radiol. 2018. PMID: 29915885. doi:10.1007/s00330-018-5556-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。